Question 1

What is FID-007?

Accepted Answer

FID-007 is a Other.

Question 2

How often does FID-007 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 8 articles.

Question 3

When was FID-007 first tracked by Ergen?

Accepted Answer

First tracked on May 21, 2026.

Question 4

When was FID-007 last mentioned in news?

Accepted Answer

Last active on Jun 01, 2026.

Question 5

What is FID-007's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is FID-007 in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving FID-007?

Accepted Answer

Fulgent FID-007 Phase 2 Results (May 21, 2026, 8 articles).

Question 8

How did the "Fulgent FID-007 Phase 2 Results" event impact FID-007?

Accepted Answer

FID-007 is the drug candidate developed by Fulgent Genetics that showed meaningful clinical activity and a favorable safety profile in combination with cetuximab for treating R/M HNSCC.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.